Take a look at JAZZ chart, the intuitions bought up the whole float years ago when it was sub $10.00, it actually traded in the .60 range around 2009. My FIRM belief is the institutions are now well positioned to run ARRY in the same manner with 100% intuitional ownership of the float. ALl you need is patience and a catalyst as our infamous CEO would say lol
1) Yesterdays SEC 8K filing aroused my suspicious, besides increasing their cash position, it moved 33 employees to a new company, the other option would be laying off all unneeded employees. Especially if the acquirer already has a (CMC) Chemistry, Manufacturing and Controls Division . For "INSTATANCE" AstraZeneca already has a CMC Unit, no need to duplicate . I can see the acquirer absorbing the remainder of the ARRAY employees (150).
2) With Institutional Ownership at 102% of float , makes me wonder what does "ALL" the big money know that the retail investor is not aware of ? The last stock I owned with 90% institutional Ownership was HGSI and it was bought out shortly there after.
Of course this is just my humble opinion, time will tell. Like most of you, I rather see the pipeline mature and commercialize their products, than a buyout in the $18.00-$22.00 range.
Opinions ? Ideas ?
MEK162 shows signs of clinical efficacy in pts with biliary tract cancer MEK162 has an acceptable safety profile at 60 mg BID Central serous-like retinopathy was manageable with dose modifications MEK162 has desirable PK propertiesthat were equivalent to that observed in prior studies An additional expansion cohort is ongoing in ptswith KRAS-or BRAF-mutant metastatic colorectal cancer
on the ASCO Website, you might also be able to google it. Waiting for a BIG Monday /Tuesday
still buying arry , 89% institutional ownership and look at their pipeline, not to mention royalties only will pay arry
you better do your homework ARRY will eat ONTY and #$%$ it out. Compare the pipelines junior
A closely watched immune system-boosting drug cocktail from Britain's AstraZeneca shows promise in advanced lung cancer, despite adverse side effects in a number of patients.
Researchers said on Wednesday that the combination of the experimental drugs MEDI4736 and tremelimumab had "a manageable safety profile with evidence of clinical activity, including in PD-L1 negative disease".